April 24, 2017 5:48pm

 

However, has sentiment really changed as the risk-on run-up responds to a political stimulus?

 

The variability of risk is still defined with low volume enhanced by swings in share pricing

I said buy-in as to the sector was oversold; however, it’s time to sell/capitalize on the strength as even the pigs are wearing lipstick … be prepared!

 

Pre-open indications:  I called a macro  

 

The truth is harsh, but reality is what it is …

 

I answer one question, in which company should investors commit and keep their money

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “BUY on weakness, it was all about risk layered with volatility and the time horizon of trading strategies

  • Reiterating, “I believe Monday’s focus should be on the oversold.”

Referencing the title, “During periods when risk is perceived as low, the risk-on risk-off theory states that investors tend to engage in higher-risk investments; when risk is perceived as high, investors will exit those equities whose momentum has dwindled.

  • The Dow soared +1.05 %, NASDAQ hit +1.24%, a new all-time intraday high and S&P 500 popped 1.08%.

Remember, investors' appetites for risk rises and falls as the sector and market slips and falls.

  • At times of high volatility and volume, investors are more likely to invest in higher-risk equities than during other periods – the day trading practice.

 

Beware, be afraid and be ready for the down slide!

 

 

What analytics were there today and why it was important in today’s sector outcomes?

One answer – politics and it’s NOT an analytic!

Politics has leached into cell therapy sector in such a way that all trades are based on a political ride versus one based on results – thus a short-term stimuli!

To be more specific, fundamentals are irrelevant.

I will point to the alternative of last week’s advance/decline lines and positive/negative closes …

… The DOW closed up +216.13 or +1.05% to 20,763.89 while the NASDAQ closed up +73.30 or +1.24% to 5,983.82 …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.9 – down -25.6% …

·         As Friday traded near 14.67 after Thursday’s near 14, Wednesday’s near 14.98,Tuesday’s near 15.04 after last Monday traded near 15 …-7% lower;

 

... The iShares Russell 2000 (IWM) indicated a positive +1.60% at the pre-open was and closed UP +1.25%;

… The iShares NASDAQ Biotechnology (IBB) indicating a positive +1.32% at the pre-open and closed UP +1.48%

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was positive with an A/DL of 30/10 and 3 flats;

·         The mid-day stayed positive with an A/DL of 30/1 and 2 flat;

·         The close was positive with an A/DL of32/10 and 1 flat;

 

… Decliners ranged from -0.98% <BLFS> to -15.98% <NWBO> in 10 equities;

… Gainers ranged from +0.06% <BSTG> to +9.68% <AST> in 32 equities;

 

Percentage gainers:

·         Asterias Biotherapeutics (NYSEMKT: AST) +9.68%,

·         Cytori (CYTX) +8.91%,

·         Sangamo (SGMO) +6.17%,

·         Regenxbio (RGNX) +4.62%,

·         Spark therapeutics (ONCE) +4.46%,

 

 

Percentage losers:

·         Northwest Bio (NWBO) -15.98%,

·         uniQure (QURE) -6.81%,

·         International Stem Cell (ISCO) -5.71%,

·         Verastem (VSTM) -4.79%,

·         Adverum (ADVM) -3.70;

 

 

Dollar gainers:

·         Bluebird bio (BLUE) +$3.25,

·         Kite Pharma (KITE) +$2.75,

·         Spark Therapeutics (ONCE) +$2.34,

·         Juno Therapeutics (JUNO) +$1.03,

·         Regenxbio (RGNX) +$0.95,

 

 

Dollar losers:

·         uniQure (QURE) -$0.36,

·         International Stem cell (ISCO) -$0.10,

·         Adverum (ADVM) -$0.10,

·         Verastem (VSTM) -$0.09,

·         VistaGen (VTGN) -0.06,

 

 

Volume standout:

·         Northwest Bio (NWBO) 2.92M shares,

·         MiMedx (MDXG) 2.547 M shares,

·         ReNeuron (RENE.L) 4 M shares

 

 

Flats:

·         Fibrocell (FCSC)

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.